摘要
目的 评估降纤酶对急性脑梗死的疗效及安全性。 方法 采用前瞻性、随机、对照试验 ,以东菱精纯克栓酶 ( DF-52 1 )和低分子右旋糖酐为对照组 ,从 1 996年 1月至 1 998年 1 0月共观察 4 81例 ,其中降纤酶组 2 89例 ,东菱组 92例 ,低右组 1 0 0例 ,共完成试验者 30 1例 ,各组份别为 1 4 9例、 70例和 82例 ,于治疗前及治疗后第 1天 ,第 3天 ,第 7天 ,第 1 4天查血浆纤维蛋白原、凝血酶原时间及血小板计数、肝肾功能等。并于治疗前及治疗后 1 ,7,1 4天评估神经功能恢复情况。 结果 降纤酶对急性脑梗死疗效显著 ,明显优于低分子右旋糖酐 ,在治疗后 1天已表现出明显效果 ,与日本生产的东菱精纯克栓酶比较疗效相似 ,发病 1 4天治疗总有效率分别为 84 .4 5%和 80 .0 0 %。同时降纤酶组与东菱组治疗后纤维蛋白原下降明显 ,于 7～ 1 4天有回升趋势 ;低右组则无明显变化。 结论 降纤酶具有与东菱精纯克栓酶相似的疗效、副作用小 ,价格明显低于东菱精纯克栓酶。认为国产降纤酶可以取代东菱精纯克栓酶 。
Objective To evaluate the effect and safety of defibrase for acute cerebral infarction Methods We disigned a prespective,randomized and controlled trial and collected 301 patients with acute cerebral infarction from Jan 1996 to Oct 1998,which were devided into three groups:149 Defbrase,70 Dongling Defibrase and 82 Dextran 40 We examined plasma fibrinogen,plasma prothrombin time test,plate count,liver function,renal function and neurological function before and after treatment Results Defibrase had good effect for acute cerebral infarction and the total efficacy after 14 days therapy was 84 45%,which was significantly higher than that of Dextran40 The plasma fibrinogen decreased significantly after treatment of Defibrase and Dongling Defibrase,and increased slightly 7~14 days later Conclution Defibrase has the same effect as Dongling Defibrase,and is much cheaper Defibrase has a wide field in the treatment of acute cerebral infarction
出处
《蛇志》
2000年第3期10-12,共3页
Journal of Snake
